A Phase II Study of Paclitaxel, Trastuzumab, and Pertuzumab for the Treatment of Metastatic HER2-Positive Breast Cancer

Protocol
10-142
Full Title
Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer
Phase
II
Purpose

Paclitaxel and trastuzumab are standard drugs used to treat breast cancer. Trastuzumab is used to treat breast cancers that produce too much of a protein called HER2.

In this study, researchers are evaluating the safety and effectiveness of combination treatment with paclitaxel, trastuzumab, and the investigational drug pertuzumab in women with HER2-positive metastatic breast cancer. Pertuzumab is similar to trastuzumab in that it is an antibody targets the HER2 protein.

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have stage IV HER2-positive breast cancer that may be untreated or could have been treated with at least one prior regimen of therapy.
  • Prior anthracycline, paclitaxel, and trastuzumab treatment are allowed, but not pertuzumab.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • Patients must be age 18 or older.

For more information about this study and to inquire about eligibility, please contact Dr. Chau Dang at 646-888-5426.

Disease(s)
Breast Cancer
Related Diseases